ProteinQure is thrilled to announce a new funding milestone, having successfully raised $11,000,000 to advance its groundbreaking research in the design of novel exotic peptides for broad therapeutic applications. As a pioneering biotech company, ProteinQure leverages the power of atomic-level simulations and artificial intelligence to develop dynamic peptides that target diseased cells with pinpoint accuracy, ultimately redefining how therapeutics are delivered. This significant capital injection will be instrumental in scaling our innovative technology platform and accelerating the development of drug delivery systems that outperform conventional treatment modalities. The funds are earmarked to enhance our research and development capabilities, expand our cross-disciplinary team, and further integrate advanced computational biology, machine learning, and software engineering into our workflows. Our unique and diverse team of experts is at the forefront of a paradigm shift in the field of drug development, daring to address complex therapeutic challenges faced by patients with previously untreatable diseases. With this investment, ProteinQure is set to increase its pipeline of novel therapeutics that promise not only improved treatment efficacy but also a reduction in side effects, ultimately paving the way for safer and more effective patient outcomes. As we continue to push the boundaries of scientific discovery and innovation, we are energized by the potential to transform the landscape of medicine. Our renewed commitment to harnessing the synergy between cutting-edge research and technological advancements marks an exciting new chapter in our journey, one that holds immense promise for reshaping healthcare and delivering hope where it is needed most.
ProteinQure Raises $11M in Series A to Revolutionize Drug Delivery with AI-Designed Exotic Peptides
Recently funded · $11.0M Series aBiotechnology
Get the full ProteinQure company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
